PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2015Journal of Clinical Investigation346 citations

Development of autophagy inducers in clinical medicine

View Full Paper
BLBeth LevineMPMilton PackerPCPatrice Codogno

Key Points

Key points are not available for this paper at this time.

Abstract

Defects in autophagy have been linked to a wide range of medical illnesses, including cancer as well as infectious, neurodegenerative, inflammatory, and metabolic diseases. These observations have led to the hypothesis that autophagy inducers may prevent or treat certain clinical conditions. Lifestyle and nutritional factors, such as exercise and caloric restriction, may exert their known health benefits through the autophagy pathway. Several currently available FDA-approved drugs have been shown to enhance autophagy, and this autophagy-enhancing action may be repurposed for use in novel clinical indications. The development of new drugs that are designed to be more selective inducers of autophagy function in target organs is expected to maximize clinical benefits while minimizing toxicity. This Review summarizes the rationale and current approaches for developing autophagy inducers in medicine, the factors to be considered in defining disease targets for such therapy, and the potential benefits of such treatment for human health.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Levine et al. (2015) studied this question.

synapsesocial.com/papers/69cfa8f632950d6ce7347e9fhttps://doi.org/10.1172/jci73938
Ask AI
Helpful
Bookmark
Share
View Full Paper